PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.82%
G&A change of 49.82% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.82%
Operating expenses change of 49.82% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
49.82%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.67%. Jim Chanos would check for waste.
9.15%
Interest expense change of 9.15% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-49.81%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-49.81%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.73%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
9.15%
Other expenses change of 9.15% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
-52.65%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.65%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-52.63%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-52.63%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-0.38%
Share count reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate strategy.
-0.38%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate strategy.